Patents by Inventor Guido Kroemer

Guido Kroemer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9132123
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: September 15, 2015
    Assignee: I.E.R.F.C. European Institute For Cystic Fibrosis Research
    Inventors: Luigi Maiuri, Valeria Raia, Fabio Borella, Guido Kroemer
  • Publication number: 20150185202
    Abstract: The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as ?133TP53, TP53?, TP53? or ?40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.
    Type: Application
    Filed: July 8, 2013
    Publication date: July 2, 2015
    Applicant: INSTITUT GUSTAVE-ROUSSY
    Inventors: Jean-Luc Perfettini, Guido Kroemer, Eric Deutsch
  • Patent number: 8865653
    Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumor. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumor to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 21, 2014
    Assignee: Institut Gustave Roussy
    Inventors: Laurence Zitvogel, Guido Kroemer
  • Patent number: 8828944
    Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumor. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumor to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: September 9, 2014
    Assignee: Institut Gustave Roussy
    Inventors: Laurence Zitvogel, Guido Kroemer, Nicolas Delahaye, Yuting Ma, Oliver Kepp
  • Publication number: 20130281313
    Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to the identification of human genes and expression products thereof which can be used to assess the prognosis of a cancer in a subject, to assess the sensitivity of a subject to a treatment of cancer, or monitor, in particular determine the efficacy, of such a treatment of cancer after a given period of time. Said human genes and expression products can further be used (i) in the prevention or treatment of cancer, in particular to determine or select the appropriate cancer treatment for a given subject and/or for a particular tumor, as well as (ii) for the screening of therapeutically active drugs.
    Type: Application
    Filed: September 1, 2011
    Publication date: October 24, 2013
    Applicant: INSTITUT GUSTAVE ROUSSY
    Inventors: Lorenzo Galluzzi, Annick Harel-Bellan, Guido Kroemer, Ken Olaussen, Jean-Charles Soria
  • Patent number: 8557517
    Abstract: The present invention relates to an in vitro method of assessing the sensitivity of a subject to a treatment of cancer, which method comprises detecting the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid or an abnormal TLR4 protein expression or activity in a sample from the subject, the presence of said mutated TLR4 nucleic acid or abnormal TLR4 expression or activity being indicative of a resistance to said treatment. The invention further provides compounds for treating or preventing a cancer in a subject having a mutated TLR4 nucleic acid or an abnormal TLR4 protein expression or activity.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: October 15, 2013
    Assignee: Institut Gustave Roussy
    Inventors: Lionel Apetoh, Guido Kroemer, Laurence Zitvogel
  • Publication number: 20130156791
    Abstract: The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing human immunodeficiency virus type 1 (HIV-1) infection. More particularly, the present invention relates to a blocking agent of a component of the purinergic signalling pathway selected from the group consisting of pannexin 1, ATP or P2Y2 receptor for use in the treatment or prevention of HIV-1 infection.
    Type: Application
    Filed: August 8, 2011
    Publication date: June 20, 2013
    Inventors: Jean-luc Perfettini, Guido Kroemer, Marie-Lise Gougeon, Mauro Placentini
  • Publication number: 20130052160
    Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition.
    Type: Application
    Filed: April 1, 2011
    Publication date: February 28, 2013
    Applicant: INSTITUT GUSTAVE ROUSSY
    Inventors: Laurence Zitvogel, Guido Kroemer, Nicolas Delahaye, Yuting Ma, Oliver Kepp
  • Patent number: 8263344
    Abstract: The present invention relates to a method for determining the susceptibility of a patient tumor cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumor cell.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: September 11, 2012
    Assignees: Institut Gustave Roussy, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Guido Kroemer, Laurence Zitvogel, Theocharis Panaretakis
  • Patent number: 8129340
    Abstract: The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: March 6, 2012
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Guido Kroemer, Laurence Zitvogel
  • Publication number: 20110229411
    Abstract: The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment.
    Type: Application
    Filed: November 27, 2008
    Publication date: September 22, 2011
    Applicants: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SUD XI
    Inventors: Lionel Apetoh, Antoine Tesniere, François Ghiringhelli, Laurence Zitvogel, Guido Kroemer
  • Publication number: 20100136137
    Abstract: This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a panHER/VEGFR2 kinase inhibitor, and b) a platinum compound, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use. The invention also relates to treating certain cancers utilizing the combination of the invention.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 3, 2010
    Inventors: Tai W. Wong, Jean Soria, Guido Kroemer
  • Publication number: 20100015653
    Abstract: The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell.
    Type: Application
    Filed: September 7, 2007
    Publication date: January 21, 2010
    Applicants: Institut Gustave Roussy, Inserm (Institut National De La Sante Et De La Recherche Medicale)
    Inventors: Guido Kroemer, Laurence Zitvogel, Theocharis Panaretakis
  • Publication number: 20100016235
    Abstract: The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer.
    Type: Application
    Filed: September 7, 2007
    Publication date: January 21, 2010
    Applicants: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Guido Kroemer, Laurence Zitvogel
  • Publication number: 20100004161
    Abstract: The present invention relates to an in vitro method of assessing the sensitivity of a subject to a treatment of cancer, which method comprises detecting the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid or an abnormal TLR4 protein expression or activity in a sample from the subject, the presence of said mutated TLR4 nucleic acid or abnormal TLR4 expression or activity being indicative of a resistance to said treatment. The invention further provides compounds for treating or preventing a cancer in a subject having a mutated TLR4 nucleic acid or an abnormal TLR4 protein expression or activity.
    Type: Application
    Filed: July 17, 2007
    Publication date: January 7, 2010
    Inventors: Lionel Apetoh, Guido Kroemer, Laurence Zitvogel
  • Patent number: 7642051
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: January 5, 2010
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Publication number: 20080299101
    Abstract: The present invention concerns a method for detecting in vitro resistance of cancer cells to a treatment by detecting in the cancer cells supernumerary nucleolar organizer regions (NOR), whereby identification of the presence of supernumerary NOR in the cancer cells is indicative of treatment resistance. The present invention also concerns a method for defining the capacity of a candidate agent to modulate NOR genes number of cancer cells by contacting the cancer cells with a candidate agent for a time sufficient to permit modulation of NOR genes number; and observing whether NOR genes number increases or decreases in said cancer cells. The present invention also provides a candidate agent that modulates NOR genes number of cancer cells obtained by the method of the invention and a composition for treating and/or preventing a cancer in a patient, comprising said candidate agent. Such a candidate agent decreases the NOR genes number in said cancer cells.
    Type: Application
    Filed: July 8, 2005
    Publication date: December 4, 2008
    Inventors: Isabelle Gourdier, Arnaud Coquelle, Bernard Dutrillaux, Guido Kroemer, Bernard Pau
  • Patent number: 7056735
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: June 6, 2006
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Publication number: 20060052285
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: July 8, 2005
    Publication date: March 9, 2006
    Applicants: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Jacotot, Guido Kroemer, Bernard Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Publication number: 20040072146
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: March 10, 2003
    Publication date: April 15, 2004
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelmann, Johan Hoebeke, Catherine Brenner-Jan, Anne-Sophie Belzacq